ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Mankind Pharma has successfully completed the interest payment and full redemption of its Non-Convertible Debentures due on October 16, 2026.
Mankind Pharma has fully redeemed its Non-Convertible Debentures, paying back the principal amount of ₹1,250 Crore on the maturity date.
Mankind Pharma Ltd confirmed payment of interest for its non-convertible debentures. This routine debt servicing update confirms the company has fulfilled its payment obligations.
Mankind Pharma will invest ₹479.60 Crore into its Dutch subsidiary to acquire a majority 70% stake in Belgian biotech firm ACTx, strengthening its innovation-led portfolio.
Mankind Pharma will acquire a 70% stake in Belgium-based Armed Cell Therapeutics for EUR 48 million to enter the CAR-T therapies market.